Brief: Dermapharm Q1 Adjusted EBITDA EUR 88.7 Million
15/05/2024 06:31
May 15 (Reuters) - Dermapharm Q1 EBITDA margin 28.7%. * Q1 EBITDA EUR 85.7 million * Q1 adjusted EBITDA margin 29.7% * Q1 revenue EUR 298.7 million
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit